blinatumomab (Blincyto) accepted for restricted use within NHSScotland

The SMC has accepted blinatumomab for the treatment of adults with Philadelphia chromosome negative, CD19 positive, B-precursor acute lymphoblastic leukaemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.

SPS commentary:

NICE has similarly approved use of blinatumomab for this indication previously.


Scottish Medicines Consortium

Resource links:

NICE TA589 (July 2019)